Xenetic Biosciences, Inc.

Listed Company

XBIOCIK 0001534525NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

$2.98M

Net Income

$-2.68M

Total Assets

—

Equity

—

Shares Out

2.29M

Op. Cash Flow

$-2.29M

Business

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immuno-oncology technologies that target neutrophil extracellular traps (NETs) to improve outcomes of difficult‑to‑treat solid tumors. It develops a proprietary DNase program (including systemic IV rhDNase I and DNase‑armored CAR T approaches) and licenses a polysialic acid‑based PolyXen drug‑delivery platform. Its activities encompass internal R&D, academic and industry collaborations, licensing and sublicensing, and reliance on contract manufacturers and CROs. It pursues clinical development and regulatory pathways in the U.S., Europe and other jurisdictions and commercializes through partners, licenses and contract manufacturing channels.

Summary from filing dated 2025-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Royalty revenue	3	3	3	2	1
Total revenue	3	3	3	2	1
Research and development	−3	−3	−3	−5	−3
General and administrative	−3	−3	−4	−4	−4
Total operating costs and expenses	−6	−7	−7	−8	−7
Loss from operations	−3	−4	−5	−7	−6
Other income (expense)	5,725	−5,708	25,380	−1,597	1,119
Interest income, net	147,997	249,861	355,757	167,152	100,467
Total other income, net	153,722	244,153	381,137	165,555	101,586
Net loss	−3	−4	−4	−7	−6
Basic net loss per share	−1.58	−2.57	−2.71	−4.61	−0.55
Diluted net loss per share	−1.58	−2.57	−2.71	−4.61	−0.55
Weighted-average shares of common stock outstanding, basic	2	2	2	1	10
Weighted-average shares of common stock outstanding, diluted	2	2	2	1	10

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	8	6	9	—	—
Prepaid expenses and other	166,294	421,954	603,828	556,094	479,399
Total current assets	8	7	10	14	19
Other assets	313,921	313,921	1	1	1
Total assets	8	7	11	15	20
Accounts payable	258,109	283,615	240,832	287,360	362,470
Accrued expenses and other current liabilities	709,916	610,648	568,753	785,796	1
Total current liabilities	968,025	894,263	809,585	1	1
Total liabilities	968,025	894,263	809,585	1	1
Commitments and contingencies (Note 11)	—	—	—	—	—
Common stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 2,293,757 and 1,544,840 shares issued as of December 31, 2025 and December 31, 2024, respectively; 2,291,056 and 1,542,139 shares outstanding as of December 31, 2025 and December 31, 2024, respectively	2,294	1,545	1,544	1,520	13,465
Additional paid in capital	212	208	208	208	206
Accumulated deficit	−200	−197	−193	−189	−183
Accumulated other comprehensive income	253,734	253,734	253,734	253,734	253,734
Treasury stock	−5	−5	−5	−5	—
Total stockholders' equity	7	6	10	14	18
Total liabilities and stockholders' equity	8	7	11	15	20

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based expense	64,787	171,814	283,085	511,480	410,437
Prepaid expenses and other	255,660	181,874	−47,734	−103,738	286,007
Other long-term assets	0	704,431	48,579	25,000	−281,946
Accounts payable, accrued expenses and other current liabilities	73,762	84,678	−263,571	−347,947	457,132
Net cash used in operating activities	−2	−3	−4	−5	−5
Net proceeds from issuance of common stock in October 2025 underwritten public offering	4	0	—	0	11
Net cash provided by financing activities	4	0	—	0	11
Net change in cash	2	−3	−4	−5	7
Cash paid for interest	0	0	0	0	0
Issuance of common stock from cashless exercise of purchase warrants	0	1	0	2	6
Conversion of Series B preferred stock to common stock	350	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro